Humanigen seeks FDA approval for COVID-19 drug

By The Science Advisory Board staff writers

May 28, 2021 -- Humanigen requested an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to use its drug lenzilumab in hospitalized COVID-19 patients.

This application follows positive results from the LIVE-AIR phase III clinical trial that showed lenzilumab improved the likelihood of survival without ventilation in newly hospitalized COVID-19 patients.

If you like this content, please share it with a colleague!

Related Reading

Humanigen's mAb improves outcomes in hospitalized COVID-19 patients
Humanigen is highlighting results from a phase III trial that show that its monoclonal antibody (mAb), lenzilumab, improves outcomes in hospitalized COVID-19...

Humanigen awarded 2 patents against immunotherapy toxicities
The U.S. Patent and Trademark Office has awarded Humanigen two patents for the use of lenzilumab.

Humanigen, Avid enter COVID-19 therapy manufacturing agreement
Contract development and manufacturing organization Avid Bioservices and Humanigen have entered into a manufacturing services agreement to expand production...

Ajinomoto to up production of Humanigen's COVID-19 drug
Ajinomoto Bio-Pharma Services and Humanigen are expanding their manufacturing agreement for the fill-finish supply of lenzilumab, an investigational COVID-19...

Humanigen expands partnership with BARDA for COVID-19 mAb manufacturing
Humanigen has expanded its cooperative research and development agreement with the U.S. Department of Defense Joint Program Executive Office for Chemical,...